Skip to main content

Table 3 Clinical factors associated with HPD by univariate and multivariate analyses (n = 155)a

From: The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy

 

Univariate

Multivariate

HR (95% CI)

P-value

HR (95% CI)

P-value

Age, ≥65 vs < 65

0.49 (0.20–1.18)

0.1115

  

Gender, Female vs. Male

0.35 (0.10–1.24)

0.1039

  

ECOG, 2 ~ 3 vs. 0 ~ 1

10.67 (0.93–122.33)

0.0572

6.39 (0.48–8575)

0.1613

Smoking (pack.year), ≥20 vs. < 20

2.75 (0.97–7.75)

0.0563

5.62 (1.59–19.78)

0.0072

PD-L1 expression > 1 vs ≤1

0.28 (0.12–0.68)

0.0049

0.35 (0.13–0.93)

0.0355

Oncogenic driver mutation, any one vs. no

3.14 (1.17–8.39)

0.0227

3.21 (0.97–10.60)

0.0552

EGFR mutation, positive vs. negative

2.32 (0.74–7.27)

0.1483

  

No. of metastatic site, ≥3 vs. < 3

3.74 (1.43–9.79)

0.0073

3.53 (1.13–10.99)

0.0297

No. of treatment line before IO, ≥4 vs. < 4

2.30 (0.73–7.21)

0.1526

  
  1. a Non evaluable group and Non-HPD PD group were excluded
  2. HPD hyperprogressive disease, HR hazard ratio, ECOG European Cooperative Oncology Group, PD-L1 programmed death-ligand 1, EGFR epidermal growth factor receptor, IO immune oncology therapy